TrialCancer immunology, immunotherapy : CII2024

Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.

Jhe-Cyuan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.